ViiV Healthcare's Head of R&D, Dr. Kimberly Smith, meets with Bloomberg Intelligence senior analyst John Murphy to discuss the evolution of HIV therapy since the 1990s, what she sees as providing the next steps of treatment innovation and how close science may be to a cure. A wide-ranging discussion in this episode also includes topics such as drug access, pricing and clinical trial diversity.

See omnystudio.com/listener for privacy information.

"If all goes well, Heartbeat Health will be a household name for the first referral from primary care for cardiology. It'll be easier than everyone else out there and less expensive than other referrals." Dr. Jeff Wessler, CEO and Founder of Heartbeat Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Dr. Wessler joins BI analyst Jonathan Palmer to discuss the genesis of Heartbeat's decentralized cardiology practice, how the company iterated from a brick and mortar clinic to a virtual platform to speed access, and why keeping patient care at the center has improved outcomes.

See omnystudio.com/listener for privacy information.

Generate Biomedicines’ proprietary platform aims to use generative biology to upend traditional drug development across therapeutic protein modalities. Gevorg Grigoryan, chief technology officer, and Alex Snyder, chief medical officer, sit down with BI analysts Andrew Galler and Sam Fazeli to discuss the general state of AI in drug development and the unique capabilities of the Generate platform in developing novel biologics.

See omnystudio.com/listener for privacy information.